| Short-term low-dose secondary prophylaxis for severe/moderate haemophilia A children is beneficial to reduce bleed and improve daily activity, but there are obstacle in its execution: a multi-centre pilot study in China. | |
| | |
MedLine Citation:
|
PMID: 23231016 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
We recently showed in a single centre trial that low-dose secondary prophylaxis in severe/moderate haemophilia patients with arthropathy is feasible and beneficial. However, this regimen has not been validated in a multicentre setting and what obstacles are there to prophylaxis remain unclear. (i) Benefit study: to confirm the benefits of similar prophylaxis protocol in severe/moderate haemophilia A (HA) in a multicentre setting in China. (ii) Follow-up obstacle study: to investigate obstacles in compliance to prophylaxis treatment. (i) Benefit study: severe/moderate HA children with arthropathy from 15 centres were enrolled to undergo an 8-week on-demand treatment, followed by 6 to 12-week low-dose secondary prophylaxis. Outcomes compared in the two periods include joint and severe bleeding, daily activities and factor consumption. (ii) Obstacle study: questionnaires to investigators to collect data on patient and centre factors contributing to inability to comply with prophylaxis. We enrolled 191 patients from 15 centres. Sixty-six (34.6%) from three centres completed the prophylaxis protocol, and they had significantly decreased bleeding (78.8% haemarthrosis and 68.9% severe bleedings) and improved daily activities with no increase in factor consumption over that in the on-demand therapy period. The remaining 125 patients from 12 centres were not compliant to the prophylaxis protocol; questionnaire data indicated that the major obstacles were inability of patients/parents to accept (41.7%) or to adhere (33.3%) to the prophylaxis protocol, mostly because of failure to understand the benefits and to accept the frequent injections. Non-availability of a centre comprehensive care team was another important determinant. Short-term low-dose secondary prophylactic therapy is beneficial without increasing factors consumption for severe/moderate HA with arthropathy in a multi-centre setting in China. Obstacles to overcome must include improvement in comprehensive care and in education to patient/parents and healthcare personnel. |
| | |
Authors:
|
L Tang; R Wu; J Sun; X Zhang; X Feng; X Zhang; K-H Luke; M-C Poon |
Related Documents
:
|
23080236 - More frequent visits to wound care clinics result in faster times to close diabetic foo... 22116796 - Bronchoscopic lung volume reduction coil treatment of patients with severe heterogeneou... 23440016 - Impact of bispectral index monitoring on postoperative delirium in patients undergoing ... 23210066 - Adding different doses of intrathecal magnesium sulfate for spinal anesthesia in the ce... 23170866 - Development of sense of coherence during two group interventions. 10807486 - A multicenter comparison of cognitive-behavioral therapy and interpersonal psychotherap... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Haemophilia : the official journal of the World Federation of Hemophilia Volume: 19 ISSN: 1365-2516 ISO Abbreviation: Haemophilia Publication Date: 2013 Jan |
Date Detail:
|
Created Date: 2012-12-12 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9442916 Medline TA: Haemophilia Country: England |
Other Details:
|
Languages: eng Pagination: 27-34 Citation Subset: IM |
Copyright Information:
|
© 2012 Blackwell Publishing Ltd. |
Affiliation:
|
Hemophilia Work Group, Beijing Children's Hospital affiliated to Capital Medical University, Beijing, China. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Joint TGF-beta Type II Receptor Expressing Cells: Ontogeny and Characterization as Joint Progenitors...
Next Document: Antioxidant ?-Carotene does not Quench Singlet Oxygen in Mammalian Cells.